Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(1):79–87. doi: 10.1038/bjc.1998.446

Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells.

Grunt ThW 1, E Dittrich 1, M Offterdinger 1, S M Schneider 1, Ch Dittrich 1, H Huber 1
PMCID: PMC2062943  PMID: 9662255

Abstract

We investigated the effects of all-trans retinoic acid (ATRA) and fenretinide (4-HPR) on c-erbB-2 expression in SK-BR-3, BT-474 and MCF-7 breast cancer cells and on the growth, differentiation, apoptosis and cisplatin (CDDP) sensitivity of SK-BR-3 cells. It has been reported that oestrogen inhibits c-erbB-2 in oestrogen receptor-positive breast cancer cells. Using ELISA, Western and Northern analysis we have demonstrated that ATRA and 4-HPR exert similar effects down-regulating c-erbB-2 protein and mRNA in c-erbB-2-overexpressing SK-BR-3 and BT-474 and in normally expressing MCF-7 cells. Both retinoids inhibit SK-BR-3 cell growth. ATRA induces cellular enlargement and flattening, suggesting epithelial differentiation. 4-HPR causes nuclear and cytoplasmic condensation, DNA fragmentation and externalization of phosphatidylserine, indicating apoptosis. c-erbB-2 expression/activity has been linked to sensitivity against CDDP. Therefore, combinations of ATRA or 4-HPR with CDDP were tested for their anti-proliferative activity. Retinoid-conditioned cells were either exposed to retinoid and CDDP (schedule I, 'continuous retinoid treatment') or to CDDP alone (schedule II, 'retinoid pretreatment'). This retinoid-conditioning followed by CDDP +/- retinoid yields stronger growth inhibition compared with unconditioned cells, which were exposed to CDDP +/- retinoid (schedule III, 'no retinoid pretreatment'). The inefficacy of schedule III indicates that retinoid-conditioning is essential for the improvement of the antiproliferative effect. The interactions in schedules I and II are synergistic for ATRA and CDDP, but slightly antagonistic for 4-HPR and CDDR However, 4-HPR + CDDP is more effective in growth inhibition than each drug alone.

Full text

PDF
79

Images in this article

81Figure 1
on p.81
82Figure 3
on p.82
82Figure 4
on p.82
83Figure 5
on p.83
83Figure 6
on p.83

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arteaga C. L., Winnier A. R., Poirier M. C., Lopez-Larraza D. M., Shawver L. K., Hurd S. D., Stewart S. J. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 1994 Jul 15;54(14):3758–3765. [PubMed] [Google Scholar]
  2. Bacus S. S., Kiguchi K., Chin D., King C. R., Huberman E. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol Carcinog. 1990;3(6):350–362. doi: 10.1002/mc.2940030607. [DOI] [PubMed] [Google Scholar]
  3. Benz C. C., Scott G. K., Sarup J. C., Johnson R. M., Tripathy D., Coronado E., Shepard H. M., Osborne C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992;24(2):85–95. doi: 10.1007/BF01961241. [DOI] [PubMed] [Google Scholar]
  4. Bissonnette R. P., Echeverri F., Mahboubi A., Green D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature. 1992 Oct 8;359(6395):552–554. doi: 10.1038/359552a0. [DOI] [PubMed] [Google Scholar]
  5. Caliaro M. J., Vitaux P., Lafon C., Lochon I., Néhmé A., Valette A., Canal P., Bugat R., Jozan S. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br J Cancer. 1997;75(3):333–340. doi: 10.1038/bjc.1997.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Costa A., De Palo G., Decensi A., Formelli F., Chiesa F., Nava M., Camerini T., Marubini E., Veronesi U. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Ann N Y Acad Sci. 1995 Sep 30;768:148–162. doi: 10.1111/j.1749-6632.1995.tb12118.x. [DOI] [PubMed] [Google Scholar]
  7. D'Souza B., Berdichevsky F., Kyprianou N., Taylor-Papadimitriou J. Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. Oncogene. 1993 Jul;8(7):1797–1806. [PubMed] [Google Scholar]
  8. De Bortoli M., Dati C., Antoniotti S., Maggiora P., Sapei M. L. Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):21–25. doi: 10.1016/0960-0760(92)90183-j. [DOI] [PubMed] [Google Scholar]
  9. Fanjul A. N., Delia D., Pierotti M. A., Rideout D., Yu J. Q., Pfahl M., Qiu J. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem. 1996 Sep 13;271(37):22441–22446. doi: 10.1074/jbc.271.37.22441. [DOI] [PubMed] [Google Scholar]
  10. Fanjul A., Dawson M. I., Hobbs P. D., Jong L., Cameron J. F., Harlev E., Graupner G., Lu X. P., Pfahl M. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature. 1994 Nov 3;372(6501):107–111. doi: 10.1038/372107a0. [DOI] [PubMed] [Google Scholar]
  11. Fenaux P., Chomienne C., Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol. 1997 Feb;24(1):92–102. [PubMed] [Google Scholar]
  12. Flicker S. H., Schneider S. M., Offterdinger M., Dittrich E., Fazeny B., Valenta R., Huber H., Dittrich C., Grunt T. W. Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cells. Cancer Lett. 1997 May 1;115(1):63–72. doi: 10.1016/s0304-3835(97)04715-0. [DOI] [PubMed] [Google Scholar]
  13. Formelli F., Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res. 1993 Nov 15;53(22):5374–5376. [PubMed] [Google Scholar]
  14. Grunt T. W., Oeller H., Somay C., Dittrich C. Different propensity for spontaneous differentiation of cell clones isolated from the human ovarian surface epithelial cell line HOC-7. Differentiation. 1993 May;53(1):45–50. doi: 10.1111/j.1432-0436.1993.tb00644.x. [DOI] [PubMed] [Google Scholar]
  15. Grunt T. W., Saceda M., Martin M. B., Lupu R., Dittrich E., Krupitza G., Harant H., Huber H., Dittrich C. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer. 1995 Nov 15;63(4):560–567. doi: 10.1002/ijc.2910630417. [DOI] [PubMed] [Google Scholar]
  16. Grunt T. W., Somay C., Ellinger A., Pavelka M., Dittrich E., Dittrich C. The differential effects of N,N-dimethylformamide and transforming growth factor-beta 1 on a human ovarian cancer cell line (HOC-7). J Cell Physiol. 1992 Apr;151(1):13–22. doi: 10.1002/jcp.1041510104. [DOI] [PubMed] [Google Scholar]
  17. Grunt T. W., Somay C., Oeller H., Dittrich E., Dittrich C. Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells. J Cell Sci. 1992 Oct;103(Pt 2):501–509. doi: 10.1242/jcs.103.2.501. [DOI] [PubMed] [Google Scholar]
  18. Grunt T. W., Somay C., Pavelka M., Ellinger A., Dittrich E., Dittrich C. The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells. J Cell Sci. 1991 Nov;100(Pt 3):657–666. doi: 10.1242/jcs.100.3.657. [DOI] [PubMed] [Google Scholar]
  19. Hancock M. C., Langton B. C., Chan T., Toy P., Monahan J. J., Mischak R. P., Shawver L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991 Sep 1;51(17):4575–4580. [PubMed] [Google Scholar]
  20. Hynes N. E., Gerber H. A., Saurer S., Groner B. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem. 1989 Feb;39(2):167–173. doi: 10.1002/jcb.240390208. [DOI] [PubMed] [Google Scholar]
  21. Kalthoff H., Roeder C., Gieseking J., Humburg I., Schmiegel W. Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8972–8976. doi: 10.1073/pnas.90.19.8972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kazmi S. M., Plante R. K., Visconti V., Lau C. Y. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res. 1996 Mar 1;56(5):1056–1062. [PubMed] [Google Scholar]
  23. Krupitza G., Hulla W., Harant H., Dittrich E., Kallay E., Huber H., Grunt T., Dittrich C. Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. Int J Cancer. 1995 May 29;61(5):649–657. doi: 10.1002/ijc.2910610511. [DOI] [PubMed] [Google Scholar]
  24. Marth C., Cronauer M. V., Doppler W., Ofner D., Ullrich A., Daxenbichler G. Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. Int J Cancer. 1992 Jan 2;50(1):64–68. doi: 10.1002/ijc.2910500114. [DOI] [PubMed] [Google Scholar]
  25. Martin S. J., Reutelingsperger C. P., McGahon A. J., Rader J. A., van Schie R. C., LaFace D. M., Green D. R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995 Nov 1;182(5):1545–1556. doi: 10.1084/jem.182.5.1545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Nehmé A., Albin N., Caliaro M. J., Guichard S., Jozan S., Julia A. M., Bugat R., Canal P. Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell lines. Int J Cancer. 1995 May 29;61(5):643–648. doi: 10.1002/ijc.2910610510. [DOI] [PubMed] [Google Scholar]
  27. Nugent A., McDermott E., Duffy K., O'Higgins N., Fennelly J. J., Duffy M. J. Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer. Clin Chem. 1992 Aug;38(8 Pt 1):1471–1474. [PubMed] [Google Scholar]
  28. Paik S. Clinical significance of erbB-2 (HER-2/neu) protein. Cancer Invest. 1992;10(6):575–579. doi: 10.3109/07357909209024819. [DOI] [PubMed] [Google Scholar]
  29. Pellegrini R., Mariotti A., Tagliabue E., Bressan R., Bunone G., Coradini D., Della Valle G., Formelli F., Cleris L., Radice P. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ. 1995 Jul;6(7):863–869. [PubMed] [Google Scholar]
  30. Pietras R. J., Fendly B. M., Chazin V. R., Pegram M. D., Howell S. B., Slamon D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994 Jul;9(7):1829–1838. [PubMed] [Google Scholar]
  31. Read L. D., Keith D., Jr, Slamon D. J., Katzenellenbogen B. S. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res. 1990 Jul 1;50(13):3947–3951. [PubMed] [Google Scholar]
  32. Rustin G. Synopsis of workshop on treatment of solid tumours. Leukemia. 1994;8 (Suppl 3):S85–S86. [PubMed] [Google Scholar]
  33. Saceda M., Grunt T. W., Colomer R., Lippman M. E., Lupu R., Martin M. B. Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology. 1996 Oct;137(10):4322–4330. doi: 10.1210/endo.137.10.8828492. [DOI] [PubMed] [Google Scholar]
  34. Sacks P. G., Harris D., Chou T. C. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer. 1995 May 4;61(3):409–415. doi: 10.1002/ijc.2910610322. [DOI] [PubMed] [Google Scholar]
  35. Somay C., Grunt T. W., Mannhalter C., Dittrich C. Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells. Br J Cancer. 1992 Jul;66(1):93–98. doi: 10.1038/bjc.1992.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tang C. K., Perez C., Grunt T., Waibel C., Cho C., Lupu R. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res. 1996 Jul 15;56(14):3350–3358. [PubMed] [Google Scholar]
  37. Trauth B. C., Klas C., Peters A. M., Matzku S., Möller P., Falk W., Debatin K. M., Krammer P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989 Jul 21;245(4915):301–305. doi: 10.1126/science.2787530. [DOI] [PubMed] [Google Scholar]
  38. Tsai C. M., Chang K. T., Perng R. P., Mitsudomi T., Chen M. H., Kadoyama C., Gazdar A. F. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst. 1993 Jun 2;85(11):897–901. doi: 10.1093/jnci/85.11.897. [DOI] [PubMed] [Google Scholar]
  39. Veronesi U., De Palo G., Costa A., Formelli F., Decensi A. Chemoprevention of breast cancer with fenretinide. IARC Sci Publ. 1996;(136):87–94. [PubMed] [Google Scholar]
  40. Yu D., Liu B., Tan M., Li J., Wang S. S., Hung M. C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996 Sep 19;13(6):1359–1365. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES